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Pituitary adenomas comprise a heterogeneous subset of pathologies causing serious comorbidities, which
would benefit from identification of novel, commonmolecular/cellular biomarkers and therapeutic targets.
The ghrelin system has been linked to development of certain endocrine-related cancers. Systematic analysis
of the presence and functional implications of some components of the ghrelin system, including native
ghrelin, receptors and the recently discovered splicing variant In1-ghrelin, in human normal pituitaries (n
5 11) and pituitary adenomas (n 5 169) revealed that expression pattern of ghrelin system suffers a clear
alteration in pituitary adenomasas comparedwith normal pituitary, where In1-ghrelin is markedly
overexpressed. Interestingly, in cultured pituitary adenoma cells In1-ghrelin treatment (acylated peptides at
100 nM; 24–72 h) increasedGH andACTH secretion, Ca21 and ERK1/2 signaling and cell viability, whereas
In1-ghrelin silencing (using a specific siRNA; 100 nM) reduced cell viability. These results indicate that an
alteration of the ghrelin system, specially its In1-ghrelin variant, could contribute to pathogenesis of
different pituitary adenomas types, and suggest that this variant and its related ghrelin system could provide
new tools to identify novel, more general diagnostic, prognostic and potential therapeutic targets in
pituitary tumors.
G
hrelin gene (GHRL) products and associated receptors, proteins, and enzymes are emerging as an
intricate and pleiotropic regulatory system involved in a plethora of physiological and pathological
functions, including hormonal secretions and tumor development and progression1,2. GHRL gene
encompasses four coding exons3 that alternatively combine, through splicing processes, to generate several
mature and functional mRNAs, which, after translation, generate prepro-peptides that are further processed
by the action of proteolytic enzymes to originate biologically active peptides4 (e.g. native ghrelin, obestatin, etc.).
Among them, special attention has been dedicated to ghrelin itself, a 28-aa peptide hormone, including its
acylated (AG) and unacylated forms, obestatin5, and more recently, to their splicing variants1,4,6–9. Among these
splicing variants is the In1-ghrelin variant, which is generated by retention of intron 1 (In1) resulting in an
alteration in the amino acids (aa) sequence of the C-terminal portion as compared with native-ghrelin. However,
In1-ghrelin variant shares the signal peptide and an initial portion of 13 aa of its peptide sequence with native
ghrelin, which includes the first 5-amino acids (aa) that comprises the minimum sequence required for ghrelin
acylation byMBOAT4, the enzyme responsible for ghrelin acylation10,11, and for binding and activation of GHSR-
1a1,4. Therefore, In1-ghrelin variant would encode a different prepro-peptide that conserves the initial aa of native
ghrelin but presents a different C-terminal tail, and whose expression has been demonstrated in several human
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healthy tissues, and has been found to be overexpressed in breast
cancer6. Moreover, the orthologous counterparts of the human In1-
ghrelin variant have also been found in mice (named In2-ghrelin12)
and in a non-human primate model6, which suggest that this new
variant might exert an important physiological role that is conserved
across mammalian species.
GHRL gene-derived transcripts/peptides are produced by the pitu-
itary gland6,13,14, and seem to be involved in the regulation of the
normal pituitary secretory pattern1,15–17. In contrast to the growing
number of biologically active ghrelin gene-derived peptides, only a
single receptor, transcribed from GHSR gene, named GHSR1a, has
hitherto been identified as unequivocal endogenous functional bind-
ing target for AG, while a physiological function has not been
unequivocally ascribed to its shorter, truncated splicing isoform
GHS-R1b18. On the other hand, the receptor(s) mediating the actions
of unacylated-ghrelin, obestatin, In1-ghrelin and other splicing var-
iants remain elusive, if not controversial18. The enzyme responsible
for ghrelin acylation, MBOAT4, belongs to the superfamily of mem-
brane bound O-acyltransferases, and is commonly referred to as
ghrelin-O-acyltransferase (GOAT)10,11. This enzyme has been found
to be expressed in a variety of human and rodent tissues19,20, includ-
ing the pituitary, where it has been proposed that locally produced
GOAT might possibly be active to convertlocally produced or cir-
culating non-acylated forms of proghrelin or proIn1-ghrelin to their
acylated forms to mediate tissue-specific effects20.
The first evidence indicating that ghrelin system could be
involved in tumor development and/or progression was the finding
that GHSR1a was expressed in normal and tumoral pituitaries21.
Thereafter, ghrelin was also found in various types of pituitary
tumors13,22,23, thus suggesting a complex autocrine/paracrine role of
the ghrelin system in pituitary pathogenesis. In fact, ghrelin, GHSR1a
and the truncatedGHSR1b have been found to be expressed in awide
variety of endocrine-related tumors, including pituitary adenomas,
neuroendocrine tumors and breast and prostate tumors6,13,21,24,25.
Additionally, MBOAT4 and In1-ghrelin variant expression has been
observed in breast6,26 and prostate27–29 cancers but their presence in
pituitary adenomas is still to be determined.
Although some of the components of the ghrelin system seems to
exert autocrine/paracrine regulatory actions and could thus hold
potential as a diagnostic, prognostic or therapeutic target in several
tumoral pathologies, including pituitary adenomas, its exact role in
tumor development and progression is still uncertain. Moreover, the
presence of MBOAT4 and In1-ghrelin has not yet been determined
in pituitary adenomas. Therefore, the aim of this study was to sys-
tematically analyze, for the first time, the side-by-side presence of
different components of the ghrelin system: native ghrelin, In1-ghre-
lin variant, MBOAT4 enzyme, GHSR1a and GHSR1b, in normal
pituitaries and in all major types of human pituitary tumors. In
addition, we used pituitary adenoma primary cell cultures and a
mouse corticotropinoma cell line (AtT-20) to compare the direct
effects of native ghrelin and In1/In2-ghrelin variant administration
on selected functional parameters to better define the pathophysio-
logical significance of this regulatory system in pituitary tumors.
Results
Ghrelin system is altered in pituitary adenomas compared to
normal pituitary. All components of the ghrelin system examined
(native ghrelin, In1-ghrelin variant, GHSR1a, GHSR1b and MBOAT4
enzyme) were expressed in normal pituitaries (Figure 1 and Sup-
plemental Figure-1). Expression of MBOAT4 and that of ghrelin
receptors were also found at appreciable levels in normal pituitaries
(Figure 1). Interestingly, the expression pattern of ghrelin system
components was markedly altered in pituitary adenomas compared
with normal pituitaries. Specifically, median expression levels of
native ghrelin were significantly elevated in GH-omas, while no
significant changes were observed in ACTH-omas, NFPAs or
PRL-omas compared with normal pituitaries (Figure 1 and
Supplemental Figure-1). In contrast, the expression of In1-ghrelin
was significantly elevated in all types of pituitary adenomas
analyzed (Figure 1 and Supplemental Figure-1), suggesting a
potential common relevant role in pituitary tumors pathogenesis.
Expression of MBOAT4 was slightly, but significantly, reduced in
ACTH-omas and NFPAs compared to normal pituitaries, while no
significant changes were observed in GH-omas and PRL-omas
(Figure 1 and Supplemental Figure-1). In the case of ghrelin
receptors, a pronounced overexpression of GHSR1a and GHSR1b
was observed in GH-omas and, similarly, an elevation in the
expression of both receptors was also observed in ACTH-omas,
which was only statistically significant for GHSR1b. In contrast,
median expression levels of both receptors were reduced in NFPAs,
and no changes were observed in PRL-omas (Figure 1 and
Supplemental Figure-1). Although caution should be exerted when
comparing normal pituitary tissues (which contain a mixture of
pituitary cell subtypes) and pituitary adenomas (though to be
mono/oligoclonal in origin), it should be noted that the careful use
of this type of comparison has been generally accepted13,30 as it
provides potentially valuable and informative insights, and may
help to set the stage for future investigations to elucidate the
putative physiological role(s) for the ghrelin system in normal
pituitaries and pituitary adenomas. In1-ghrelin expression levels
correlated with those of MBOAT4 in GH-omas, ACTH-omas, and
NFPAs, but not in normal pituitaries (no correlation analysis were
performed in PRL-omas due to insufficient number of samples),
which may suggest that In1-ghrelin could be functionally linked
with MBOAT4 in pituitary adenomas. Expression levels of ghrelin
and MBOAT4 correlated in GH-omas and NFPAs but not in ACTH-
omas and normal pituitaries (Supplemental Table-2). Inasmuch as
In1-ghrelin expression was consistently elevated in all pituitary
adenomas, and its expression correlated with that of MBOAT4 in
pituitary adenomas (and not in normal pituitaries), we considered of
foremost interest to explore the putative role of this novel ghrelin
gene variant in the pathophysiology of pituitary tumors.
In1-ghrelin peptides induce intracellular signaling activation in
pituitary adenoma cells. To test the capacity of In1-ghrelin peptides
to induce functional responses in pituitary tumor cells, we measured
the kinetics of free cytosolic calcium concentration ([Ca21]i) in single
cells derived from GH-omas, ACTH-omas, NFPAs and PRL-omas,
as well as the levels of phosphorylation of two signaling pathways
(MAPK and Akt; p-ERK1/2 or p-Akt, respectively) in GH-omas in
response to treatment with acylated In1-ghrelin peptides as
compared with that of AG. Calcium is a relevant second messenger
well known for its involvement on pituitary cell physiology, where it
triggers hormone secretion and has thus been widely used to evaluate
pituitary cell function23. Therefore, two putative In1-ghrelin derived
peptides (In1-19 and In1-40) were chemically synthesized and
employed, in parallel with AG. AG induced [Ca21]i changes in the
majority of cells derived from all GH-omas and ACTH-omas tested
(Table 2). Particularly, 74% of the cells from GH-omas and ACTH-
omas responded to AG doubling the [Ca21]i levels. Remarkably, both
In1-ghrelin peptides induced similar responses inmost GH-oma and
ACTH-oma cells, with In1-19, in general terms, being more efficient
than In1-40. In all cases, the increase in [Ca21]i levels were slightly
lower than those elicited by AG (Table 2). In NFPA, AG and In1-
ghrelin peptides elicited [Ca21]i responses in approximately 50% of
the adenoma cultures, with lower proportion of responsive cells
(29%, 18% and 10%, respectively) and lower maximal responses
than those observed in GH- and ACTH-omas. Finally, PRL-oma
cells showed a very modest response to ghrelin system peptides
with less than 20% of cells increasing [Ca21]i levels in response to
AG and less that 10% of cells responding to In1-ghrelin peptides in
only a subset of the PRL-omas. In1-ghrelin peptides exhibited a
www.nature.com/scientificreports
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slightly lower potency than AG in all parameters tested in NFPAs
and PRL-omas (Table 2). Altogether, these results demonstrate that
AG and In1-ghrelin peptides impact Ca21 signaling in pituitary
adenoma cell cultures. To test the possibility that In1-ghrelin
peptides could bind/activate GHSRs, CHO-K1 cells stably
transfected with either GHSR1a or GHSR1b were employed to
analyze [Ca21]i levels in response to In1-ghrelin peptides. Both,
In1-19 and In1-40 induced [Ca21]i changes in GHSR1a-
Figure 1 | Expression profile of ghrelin system components in normal and tumoral pituitaries. The expression of ghrelin system components (ghrelin,
In1-ghrelin variant, MBOAT4, GHSR1a and GHSR1b) was determined by qPCR in a battery of 169 pituitary adenomas (including 76 GH-omas, 29
ACTH-omas, 57 NFPAs and 7 PRL-omas) and compared to the expression levels found in 11 normal pituitaries (NPs). Data represent median 6
interquartile range of absolute expression levels (copy number) of each transcript adjusted by the expression levels of a control gene (ACTB). Asterisks
(*, p , 0.05; **, p , 0.01 and ***, p , 0.001) indicate data that differ from normal pituitary expression by Mann-Whitney U test.
Table 1 | Demographic and clinical parameters of patients included in this study
GH-omas ACTH-omas NFPAs PRL-omas
Number of cases 76 29 57 7
Mean age (years) 42.7 35.9 56.5 32.7
Gender (% of women) 51% 75% 39.6% 42.8%
Tumor size (% macroadenomas) 92% 36% 100% 100%
Extrasellar growth 84% 60% 87% 50%
www.nature.com/scientificreports
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transfected cells, with similar EC50 to that exhibited by ghrelin
(Supplemental Table-3); while GHSR1b-transfected cells did not
respond to any of the peptides tested (EC50 . 3000); therefore
suggesting that In1-ghrelin peptides can act, at least in part,
through GHSR1a. Nevertheless, responses to AG18 and In1-
ghrelin (data not shown) have been found in GHSR-lacking
cells (e.g. prostate cell lines), suggesting the existence of
additional receptors of the ghrelin system. Interestingly,
treatment with both AG and acylated In1-19 induced a clear
increase on p-ERK1/2 in somatotropinomas as compared to
vehicle treated controls (Figure 2A), whereas only AG, but not
In1-19, was able to increase p-Akt levels (Figure 2B).
In1-ghrelin peptides induce hormone secretion from pituitary
adenoma cells. To confirm that the responsiveness of pituitary
adenoma cells to In1-ghrelin peptides was translated into further
functional outcomes, in vitro hormone secretion was assessed in a
subset of tumors in response to In1-ghrelin peptides, and, when cells
were available, also to AG. AG and In1-ghrelin peptides, similarly
and significantly, increased GH secretion in GH-omas (4 h and 24 h
Table 2 | Results from free cytosolic calcium kinetics assays in tumoral pituitary cells in response to ghrelin gene derived peptides
GH-omas
# samples Cells analyzed % cell resp. % Max. Error T resp. Error
AG 27/27 1500 74.0 199.4 9.7 18.9 2.2
In1-19 13/15 983 60.4 179.3 12.6 15.9 1.4
In1-40 9/13 520 49.2 142.7 6.4 17.6 3.1
ACTH-omas
# samples Cells analyzed % cell resp. % Max. Error T resp. Error
AG 9/9 742 74.1 217.6 19.0 14.3 6.6
In1-19 3/5 230 43.9 187.5 35.2 20.0 8.9
In1-40 3/4 143 37.8 161.1 8.0 25.0 1.3
NFPA
# samples Cells analyzed % cell resp. % Max. Error T resp. Error
AG 9/15 408 29.4 162.0 9.1 23.6 7.9
In1-19 7/12 367 18.0 152.8 10.9 14.0 3.0
In1-40 1/6 29 10.3 118.7 2.3 55.0 8.5
PRL-omas
# samples Cells analyzed % cell resp. % Max. Error T resp. Error
AG 2/6 217 19.8 178.5 1.4 35.1 7.9
In1-19 1/5 160 4.4 155.3 7.5 18.6 5.0
In1-40 1/3 88 8.0 147.5 8.8 29.3 4.8
#samples: number of responsive samples of the total of samples analyzed.
Cells analyzed: total of individual cells analyzed.
% cell resp.: percentage of responsive cells in responsive samples.
%Max.: percentage of maximum response.
T resp.: time of maximum response.
Figure 2 | Basal ghrelin- and In1-19-induced phosphorylation of ERK1/2 and Akt in somatotropinomas. Representative Western Blots and
quantification of levels of p-ERK1/2/total ERK1/2 and p-Akt/total Akt in response to ghrelin and In1-19 (100 nM) on GHomas (n 5 4). Data are
expressed as percent of vehicle-treated controls (set at 100%) within experiment. Values represent the mean 6 S.E.M. Asterisks (* p, 0.05, ** p, 0.01)
indicate significant differences between vehicle- and peptide-treatments.
www.nature.com/scientificreports
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treatments; Figure 3A). Likewise, AG and In1-ghrelin peptides
significantly increased ACTH secretion in ACTH-omas with
similar efficacy, after 24 h treatment (Figure 3B). In contrast, In1-
19 was not able to alter PRL secretion in the samples tested (n 5 2)
after 24 h treatment (Figure 3C). Unfortunately, we could not
investigate the effect of AG or In1-40 peptide in PRL-omas due to
the limited source of preparations and of the number of cells
obtained after dispersion. Finally, the results obtained in human
ACTH-omas were further supported by the use of a widely
accepted cellular model for ACTH-producing adenomas, the AtT-
20 cell line. Specifically, AtT-20 cell line expressed higher levels of
In2-ghrelin [the murine counterpart of In1-ghrelin12] compared
with native ghrelin (Figure 4A), a situation similar to that found in
human ACTH-omas where In1-ghrelin expression was higher than
native ghrelin expression (p, 0.01; data not shown). Treatment with
AG did not significantly alter basal ACTH release in AtT-20 cell line
(which might be explained by the lack of GHSR expression;
Figure 4A and 4B), while treatment with In2-ghrelin peptide
significantly increased basal ACTH release which further support
the existence of additional receptors of the ghrelin system.
In1-ghrelin enhances cell viability in pituitary adenoma cells.
Administration of AG and In1-ghrelin peptides increased cell
viability in vitro in all pituitary adenoma subtypes (Figure 5). In
particular, cell viability was significantly increased in GH-oma cell
cultures after 48 and 72 h treatment in response to AG; after 24, 48
and 72 h treatment with In1-19 and after 72 h treatment with In1-40,
with In1-19 apparently being more effective than AG and In1-40 at
72 h (Figure 5A). In ACTH-omas, AG increased cell viability at 24 h;
while, In1-19 increased cell viability at 24, 48 and 72 h, and In1-40
did not exert any effect (Figure 5B). Consistent with an effect of In1-
ghrelin on ACTH-oma cell viability, In2-ghrelin peptide stimulated
cell viability on AtT-20 cell line, while AG did not alter cell viability in
these cells (Figure 4C). Furthermore, AG and In1-ghrelin peptides
exhibited modest but consistent increments in cell viability in NFPAs,
reaching significant levels at 24 h for AG and at 48 h for In1-19
(treatment with In1-40 did not alter cell viability in NFPA-cells)
(Figure 5C). Finally, in PRL-oma cultures, AG and In1-40 but not
In1-19 elicited significant increases on cell viability (Figure 5D).
In1-ghrelin decreases apoptotic rate in GH-omas cells.
Administration of AG did not alter apoptotic rate as compared to
vehicle treated controls in GH-oma cell cultures however; treatment
with acylated In1-19 significantly reduced apoptosis in GH-omas (n
5 3; Figure 5E) and in one ACTH-oma (n 5 1; Figure 5F).
Effect of overexpression and silencing of In1-ghrelin on in vitro
cell viability. In1-ghrelin but not native ghrelin overexpression
Figure 3 | Hormone secretion in response to ghrelin and In1-ghrelin in tumoral pituitaries. Effect of 4- and/or 24-h treatment of ghrelin (100 nM) and/
or In1-ghrelin derived peptides (In1-19 and In1-40; 100 nM) on GH, ACTH and PRL release from human GH-omas (A; n 5 3–7), ACTH-omas
(B; n5 3–9), and PRL-omas (C; n5 2) primary cell cultures, respectively, determined by commercial ELISA kits. Data are expressed as percent of vehicle-
treated controls (set at 100%) within experiment. Values represent the mean 6 S.E.M. Asterisks (* p , 0.05, ** p , 0.01; *** p , 0.001) indicate
significant differences between vehicle- and peptide-treatments.
Figure 4 | Ghrelin and In2-ghrelin variant in AtT20 cell line. (A) Expression profile of the ghrelin system (Ghrelin, In2-ghrelin variant, Mboat4 enzyme
andGhsr) in AtT-20 cell line obtained by qPCR.Data represent absolutemRNAcopy number adjusted by a normalization factor (NF) calculated from the
expression levels of three control genes (Actb, Ppia and Hprt); (B) ACTH secretion in response to 4 h ghrelin and In2-ghrelin variant treatment;
(C) Cell viability in response to ghrelin and In2; IGF-1 and Paclitaxel were used as positive and negative controls, respectively. Values represent the mean
6 S.E.M of 3–5 independent experiments. Asterisks (* p , 0.05, *** p , 0.001) indicate data that significantly differ from controls.
www.nature.com/scientificreports
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increased cell viability in cultured GH-oma cells compared to
controls (mock-transfected cells) (Figure 6A). Likewise, In1-ghrelin
overexpression significantly increased cell viability in NFPA cell
cultures (Figure 6B). A similar trend was observed in ACTH-oma
cell cultures, where In1-ghrelin overexpression tended to increase cell
viability (p 5 0.10) (Figure 6C). As mentioned above, analysis of
additional treatments (i.e. native ghrelin overexpression) and time-
points could not be performed due to limited cell preparations and/or
number. Nevertheless, we implemented, as key proof of concept, the
opposite approximation, namely In1-ghrelin silencing, in a subset of
pituitary adenomas in which cultured cells were available. Validation
of the siRNA and selection of the appropriate concentration were
carried out using commercially-available cell lines that naturally
express In1-ghrelin, such as MDA-MB-231 (breast cancer cell line)
and LnCAP (prostate cancer cell line) (data not shown). Specifically,
In1-ghrelin expression silencing with a specific siRNA reduced cell
viability in two independent GH-oma as well as in two NFPA cell
cultures compared to control (scramble-transfected cells) (Figure 6D
and 6E, respectively).
Discussion
Pituitary adenomas have been commonly considered a rare tumoral
pathology due to an underestimated diagnosis and, consequently,
low incidence worldwide. However, autopsy and imaging studies
demonstrated that these tumors present an overall estimated preval-
ence of 16.7%31, thus representing the most common intracranial
Figure 5 | Cell viability and apoptosis in response to In1-ghrelin and/or ghrelin in tumoral pituitaries. Effect of 24-, 48- and/or 72-h treatment of
acylated ghrelin (100 nM) and/or acylated In1-ghrelin derived peptides (In1-19 and In1-40; 100 nM) on cell viability in human GH-omas (A; n5 5–17),
ACTH-omas (B; n 5 2–8), NFPAs (C; n 5 3–15), and PRL-omas (D; n 5 2–3) primary cell cultures, determined by alamar-blue reduction. Effect of 12–
14 h treatment with acylated ghrelin and In1-19 (100 nM) on apoptotic rate in human GH-omas (E; n 5 3) and ACTH-oma (F; n 5 1), determined by
Annexin V/Propidium Iodide staining. Data are expressed as percent of vehicle-treated controls (set at 100%) within experiment. Values represent the
mean 6 S.E.M. Asterisks (* p , 0.05, ** p , 0.01; *** p , 0.001) indicate significant differences between vehicle- and peptide-treatments.
www.nature.com/scientificreports
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Figure 6 | Cell viability in response to In1-ghrelin overexpression and silencing in tumoral pituitaries. Effect of 24-, 48- and/or 72-h overexpression of
ghrelin (Ghr) and/or In1-ghrelin (In1) on cell viability in human GH-omas (A; n 5 4–11), NFPAs (B; n 5 2–3) and ACTH-omas (C; n 5 3) primary cell
cultures, determined by alamar-blue reduction. Overexpression was induced by transfection with specific expression vectors containing the appropriate
CDS of each variant. Effect of 24- and 48-h silencing of In1-ghrelin (In1) expression on cell viability of individual human GH-omas (D; n 5 2) and
NFPAs (E; n 5 2) primary cultures, determined by alamar-blue reduction. In1-ghrelin silencing was induced by transfection with specific siRNAs.
Representative validation by qPCR of In1-ghrelin (black bar) and ghrelin (grey bar) overexpression (F), and silencing (G) of In1-ghrelin, demonstrating a
decrease of In1-ghrelinmRNA expression (black bar) but no significant decrease of ghrelin mRNA expression (grey bar). Data are expressed as percent of
control vectors (A, B, C. Mock; set at 100%) and control random siRNA (D, E. Scr: Scramble; set at 100%) within experiment, respectively. Values
represent the mean 6 S.E.M. Asterisks (* p, 0.05, ** p, 0.01; *** p, 0.001) indicate data that significantly differ from mock or scramble controls.
www.nature.com/scientificreports
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neoplasms, which are often accompanied by serious comorbidities
through mass effects and inappropriate secretion of pituitary hor-
mones. Unfortunately, establishment of effective and long-lasting
therapeutic strategies has been hampered by the fact that pituitary
adenomas comprise an extremely heterogeneous and complex subset
of tumoral pathologies, wherein the finding of common and more
global molecular and/or cellular targets for their diagnostic, pro-
gnostic and/or therapeutic treatment has been elusive.
In this work, we hypothesized that the ghrelin system could play a
role in the regulation of pituitary adenomas, based on previous
reports indicating that this system exerts relevant actions in the
control of pituitary secretions1,16,17, and that some components of
this family are altered in certain pituitary adenomas subtypes1,13,21–23.
Thus, it seemed reasonable to propose that identification of altered
components of this ghrelin systemmight be useful in the exploration
for new tools for the diagnostic, prognostic and/or therapeutic treat-
ment of pituitary adenomas. To date, a comprehensive and system-
atic analysis of several of the components of the ghrelin system has
not been implemented in parallel in an extensive collection of pitu-
itary adenomas. Moreover, the presence and functional role of the
novel ghrelin gene variants, as In1-ghrelin variant, has not been
studied in pituitary adenomas. Thus, to better define the pattern of
alteration of ghrelin system components in pituitary adenomas, we
developed a parallel analysis of the expression pattern of native-
ghrelin, In1-ghrelin variant, GHSR1a, GHSR1b and MBOAT4 in a
battery of 169 human pituitary adenomas, including GH-, ACTH-
and PRL-producing adenomas and NFPAs, compared with normal
pituitaries. In line with previous reports, we found that these
components were expressed in normal pituitaries6,13,19–21,32,33.
Interestingly, the results generated in this study reveal that, com-
pared to normal pituitaries, expression of the ghrelin system is dra-
matically altered in pituitary adenomas, which was dependent on
tumor subtype and the specific component of the ghrelin system
analyzed.
Specifically, expression of GHRL-gene derived products (ghrelin
and In1-ghrelin), GHSR1a and GHSR1b was markedly elevated in
GH-omas, whereinMBOAT4 expressionwas also slightly albeit non-
significantly increased, indicating an overall, profound upregulation
of ghrelin system in GH-omas. This study reinforces previous data
showing higher expression of ghrelin, GHSR1a and GHSR1b in GH-
omas compared to normal pituitaries22, and extend this information
by demonstrating, for the first time, the presence of appreciable levels
of MBOAT4, a key element of this family that is required to activate
ghrelin for its binding/action via GHSR1a, and would also presum-
ably acylate the In1-ghrelin variant6,13,21, which, in addition, is heavily
overexpressed in GH-omas.
In the rest of tumoral types examined, the alteration of the ghrelin
system, although apparent, was more complex. Specifically, in
ACTH-omas, where ghrelin was previously shown to be downregu-
lated13,22 and GHSR1a and GHSR1b upregulated21,22 compared with
normal pituitaries, we found similar tendencies, but with no signifi-
cant reduction in ghrelin expression and elevation in GHSR1a
expression, while GHSR1b expression was significantly elevated.
Interestingly, we found a clear upregulation of In1-ghrelin and a
reduction in MBOAT4 expression levels in ACTH-omas compared
to normal pituitaries. In fact, comparison of the two ghrelin gene
derived transcripts expression levels in ACTH-omas (and also in
AtT-20 cell line) revealed that the expression of In1-variant was
significantly higher than that of native ghrelin, which further sup-
ports a relevant role of this variant in ACTH-omas. Conversely, PRL-
omas did not exhibit altered ghrelin expression levels, as previously
reported21,22, and neither was GHSR1a and GHSR1b expression
altered, which differs with the single report of upregulated ghrelin
receptor in PRL-omas21. Remarkably, In1-ghrelin expression was
also found to be upregulated in PRL-oma samples, while MBOAT4
expression was not altered compared to normal pituitaries. Finally,
NFPA samples exhibited a high heterogeneity, probably related to
their intrinsically diverse nature, showing a slight elevation in ghrelin
expression, which is consistent with previous reports13,22, and a
reduction in GHSR1a and GHSR1b expression levels. Notably, these
receptors exhibited a remarkably elevated expression in some NFPA
samples, which could be in agreement with previous reports showing
an elevation in ghrelin receptor expression in NFPAs13,21,22. In addi-
tion, MBOAT4 expression levels were slightly downregulated in
NFPAs and, similar to that found in all the pituitary adenomas
included in this study, we found that In1-ghrelin was significantly
overexpressed in NFPAs.
Taken together, our data confirm earlier studies supporting the
existence of a profound alteration of some components of the ghrelin
system in the most predominant pituitary adenoma subtypes13,21,22,
and extend previous data by demonstrating the expression of In1-
ghrelin andMBOAT4 in pituitary adenomas, which further supports
the notion that an autocrine/paracrine functional loop involving the
ghrelin system can be in place in the pituitary, and may contribute to
the (patho)physiological control of the gland.
Indeed, our study offers new clues in the understanding of the role
of ghrelin system in the regulation of pituitary adenomas by dem-
onstrating for the first time the significant overexpression of In1-
ghrelin in all the pituitary adenoma subtypes analyzed compared to
normal pituitaries. In fact, In1-ghrelin variant is the only component
of the ghrelin system consistently overexpressed in pituitary adeno-
mas, thus suggesting a putative utility of this variant for the develop-
ment of new and more universal diagnostic, prognostic or
therapeutic tools for the management of human pituitary adenomas.
Indeed, In1-ghrelin is widely expressed in normal tissues but pro-
foundly overexpressed in pathologic conditions such as breast can-
cer, wherein it can promote proliferation of breast cancer cell lines6.
Here, we have demonstrated that the acylated In1-ghrelin could also
play a relevant pathological role in pituitary adenomas. In particular,
this study demonstrates that GH-oma cells respond to In1-ghrelin
peptides by increasing [Ca21]i, which was associated with augmented
GH secretion in vitro34. Parallel administration of AG also increased
[Ca21]i and promoted GH secretion by GH-oma cells, which is con-
sistent with previous reports showing similar effects using ghrelin-
analogs35. In addition, we demonstrate, for the first time, that treat-
ment with In1-19 increased p-ERK1/2, but not p-Akt, levels in GH-
omas. Interestingly, parallel administration with AG increased both,
p-ERK1/2 as well as p-Akt, levels in GH-oma cells, which is also
consistent with earlier findings in murine and human cell lines36–38
and, in primary pituitary cell cultures of a non-human primate
model39. Although our results on intracellular signaling pathways
([Ca21]i, as well as ERK and Akt activation) do not provide a defin-
itive, complete elucidation of the intracellular signaling pathways
involved in the response of In1-ghrelin peptide(s) and AG in GH-
omas, we believe that the data presented provide novel evidence
regarding how this novel ghrelin variant regulates some specific
intracellular signaling pathways in GH-oma cells, and suggest the
possibility that these pathways may be partially independent to those
activated by AG in these cells. A working model summarizing the
putative mechanisms and second messenger routes activated by
ghrelin and In1-ghrelin in pituitary tumor cells is summarized in
Figure 7.
Remarkably, In1-ghrelin also influenced other key, clinically rel-
evant process, such as cell viability, in these tumors, since the In1-19
peptide significantly increased cell viability. Of note, this effect is
more effective than that elicited by In1-40 peptide (p 5 0.0079 at
72 h) or by AG itself (p 5 0.0025 at 72 h), which modestly increased
GH-oma cell viability, consistent with a previous study in rat pitu-
itary somatotrope cell lines indicating that AG can stimulate cell
proliferation40. In accordance, we found that In1-ghrelin overexpres-
sion also increased viability in GHoma cells, while In1-ghrelin silen-
cing using a specific siRNA reduced cell viability, which, again,
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strongly suggests a relevant role of In1-ghrelin in GH-omas patho-
physiology. Furthermore, we found that treatment with In1-19 also
altered (decreased) apoptotic rate in GH-omas, whereas AG did not
alter apoptotic rate as compared to vehicle-treated controls, which is
in line with previous reports showing that AG treatment did not
affect the apoptotic rate in other endocrine cell types (e.g. pancreatic
cells)38. In fact, to the best of our knowledge, this is the first study
examining the direct effect of AG or In1-ghrelin variant peptide on
apoptotic rate on human GH-omas.
Overall, these results observed in response to In1-ghrelin pep-
tide(s) treatment (i.e. an increase in proliferation rate and a decrease
apoptotic rate) suggest that In1-ghrelin variant might represent a
regulatory mechanism to control tumor growth in GH-oma cells.
In line with this, it should be mentioned that these effects might be
directly associated to the activation of MAPK signaling (i.e. ERK1/2-
phosphorylation) observed in response to treatment with In1-ghre-
lin peptide, since the activation of this signaling pathway has
been commonly associated to the regulation of cell growth and
proliferation41.
In1-ghrelin peptides also increased [Ca21]i and stimulated ACTH
release from human ACTH-oma cells and from the mouse AtT-20
corticotropinoma cell line. This was also observed withAG in human
ACTH-omas, and is in line with previous data showing that AG is
able to elicit an effect on ACTH release42, likely through an increase
in [Ca21]i23. In addition, In1-ghrelin overexpression also stimulated
ACTH-oma cell viability while treatment with In1-ghrelin peptide
In1-19, but not In1-40, revealed similar effects, suggesting that In1-
19 peptide rather than In1-40 peptide could be likely responsible for
the observed effects of In1-ghrelin overexpression in ACTH-
producing derived cells. In accordance, we also found that treatment
with mouse In2-ghrelin peptide increased cell viability in AtT-20 cell
line which further supports the influence of this novel variant of the
GHRL in the control of clinically relevant endpoints (i.e. cell viability
and hormonal release) in pituitary adenomas of different species.
Moreover, it should be mentioned that we had the opportunity to
observe that In1-19 treatment was able to exert a clear inhibition in
the apoptotic rate in one ACTH-oma sample included in the study
which, together with the previous results observed in GH-omas and
ACTH-omas, further support the notion that treatment with the In1-
ghrelin peptides influences multiple, clinically relevant parameters
on human pituitary adenomas, and may thus offer the possibility of
identifying new therapeutic tools to treat these adenomas. Obviously,
future studies, using larger number of human culture samples and
additional, different types of assays are warranted to unequivocally
establish if the overexpresion of In1-ghrelin variant observed in all
the human pituitary adenomas analyzed herein is directly associated
with an increase in proliferation and a decrease in apoptotic rate
observed in these human pituitary pathologies.
In NFPAs, no functional studies had been implemented to date
and, therefore, the role of the ghrelin system in this pathology
remained unknown1. Accordingly, our study is the first to dem-
onstrate that a subset of NFPA cells is responsive to AG and In1-
ghrelin peptides in terms of [Ca21]i kinetics. More importantly, both
AG and In1-ghrelin peptides (mainly In1-19) increased NFPA cells
viability, which was further confirmed by In1-ghrelin overexpression
experiments. As proof of concept, silencing of In1-ghrelin expression
Figure 7 | Workingmodel summarizing the putativemechanisms and secondmessenger routes activated by ghrelin and In1-ghrelin in pituitary tumor
cells. The data presented here analyzing different intracellular signaling pathways indicate that ghrelin and In1-ghrelin triggers ERK1/2 and Ca21
mobilization, whereas only ghrelin activates Akt phosphorylation. We propose that an additional receptor besides GHSR1a may exist that would bind
In1-ghrelin (and possibly acylated ghrelin) to evoke functional endpoints such as hormone release or cell proliferation. It contrast neither ghrelin nor In1-
ghrelin would be able to act through GHSR1b. MBOAT4 (GOAT) is responsible for ghrelin acylation in Ser3, and as In1-ghrelin share this Ser3, it seems
plausible that In1-ghrelin may be acylated as well.
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significantly reduced NFPA cell viability, which is particularly
relevant in this kind of pituitary adenomas since themain comorbid-
ities are derived from tumor overgrowth and mass effects43.
Results using [Ca21]i kinetic assays suggested the existence of a
reduced responsiveness of PRL-omas to AG, in that only a low pro-
portion of these pituitary adenoma cells altered their [Ca21]i in res-
ponse to AG. Yet, this seems to be sufficient to elicit functional
responses since AG treatment increases PRL secretion in this and
in previous studies35. Conversely, In1-ghrelin peptides only elicited
[Ca21]i responses in a negligible percentage of PRL-oma cells, which
is in accordance with the lack of effect of these peptides in the modu-
lation of PRL release. However, In1-40 but not In1-19 peptide was
found to be as potent as AG in stimulating PRL-oma cell viability,
which is in striking contrast with that observed in other pituitary
adenoma subtypes wherein In1-19 was found to be more effective
than In1-40 in all endpoints analyzed.
In sum, the data presented herein demonstrate, for the first time, a
consistent upregulation of In1-ghrelin expression in the most pre-
dominant pituitary adenoma subtypes compared to normal pitu-
itary. Moreover, the functional data collected strongly support the
concept that In1-ghrelin substantially influences intracellular signal-
ing, hormone secretion, and cell viability in pituitary adenoma cells.
Hence, it seems reasonable to propose that the In1-ghrelin variant
could play a relevant functional role in the regulation of pituitary
adenoma pathology. As such, our results pave the way for using In1-
ghrelin variant as a new tool to explore novel and more general
diagnostic, prognostic and/or therapeutic targets in these human
pathologies, where additional studies are warranted to determine
the clinical implications of the alteration of specific components of
the ghrelin family.
Methods
Patients and samples. Human pituitary specimens were obtained during
transsphenoidal surgery from 169 patients [76 somatotropinomas, 57 non-
functioning pituitary adenomas (NFPA), 29 corticotropinomas, and 7
prolactinomas]. In addition, 11 normal pituitaries (normal pituitary) pieces were
included in the study [10 obtained from autopsies and one from a commercial source
(pool of multiple individuals); CLONTECH; Palo Alto, CA, USA]. Themethods were
carried out in accordance with the approved guidelines, including the ethical
standards of theHelsinki Declaration of theWorldMedical Association, University of
Co´rdoba/IMIBIC and University Hospital Ethics Committees; additionally informed
consent from each patient or relative, in case of autopsy, was obtained. All
experimental protocols were approved by University of Cordoba/IMIBIC licensing
committee. The phenotype of the pituitary samples collected (normal pituitaries or
adenoma subtypes) was confirmed by three separate methods: examination by an
anatomopathologist, testing the hormonal phenotype using single-cell secretion23
(not possible in the case of normal pituitaries), and molecular screening by
quantitative real-time PCR (qPCR)30. Available demographic and clinical data are
summarized in Table 1.
Peptides.Human and rodent acylated ghrelin were commercially available (SC1357,
and SC1356, respectively; PolyPeptide Laboratories, Limhamn, Sweden), while
human, In1-ghrelin, and mouse, In2-ghrelin, acylated peptides were synthesized in
collaboration with Ipsen Bioscience (Cambridge, MA, USA) and developed by CPC
Scientific (Chinese Peptide Company, Hangzhou, China; see below). Although the
mature endogenous In1/In2-ghrelin derived peptides have not yet been identified,
pre-pro-In1-ghrelin and pre-pro-In2-ghrelin precursors exhibit target sites for
protein-convertases suggesting a further proteolytic processing. As previously
reported6, In1-ghrelin precursor processing could generate 19-aa or 40-aa long
peptides (named In1-19: GSSFLSPEHQRVQVRPPHK and In1-40:
GSSFLSPEHQRVQVRPPHKAPHVVPALPLSNQLCDLEQQR), which share with
native ghrelin the initial 13-aa, including the acylation site at Ser3. On the other hand,
we have previously reported12 that In2-ghrelin precursor processing could generate a
single32-aa long peptide (named In2-ghrelin: GSSFLSPEHQKAQVSQSVSL-
SPHIYPDLCVCV), and similarly share with native mouse ghrelin the initial 13-aa.
The acylated In1-19, In1-40 and In2-ghrelin peptides were synthesized using
manual solid-phase peptide synthesis starting with Fmoc-Lys(Boc)-Wang resin on a
0.5 mmol scale. The resins were treated with DCM/DMF (151) for 1 h, followed by
standard Fmoc single coupling cycles with 1.5 mmol amino acid and coupling agent.
All amino acids were Fmoc-protected except for Ser 3, which was unprotected. All
amino acids were activated with HBTU or DICGly1 and HATU. Octanoic acid was
coupled to Ser3 using 23 5 mmol octanoic acid andHOBt, followed by 23 10 mmol
octanoic acid andHOBt. The peptides were then treated with a cocktail of TFA/EDT/
Thioanisole/Phenol/H2O (87.552.55552.5) for 2.5 h to remove the peptides from the
resins. The peptides were confirmed by ESI MS and analytical RP-HPLC. The
peptides were eluted with a gradient of Buffer B (0.09%TFA in 80%CH3CN/H2O) in
aqueous 0.1% TFA. The peptides solubility was determined to be 1 mg/mL in water.
Finally, peptide content was determined by AAA.
Overexpression vectors and specific siRNAs. To perform overexpression
experiments, ghrelin sequence was purchased, cloned in pCMV-Sport6-vector
(Harvard Cancer Center, Boston, MA, USA) and was subcloned into the expression
vector pCDNA3.11 (Life Technologies, Grand Island, NY, USA). In1-ghrelin
sequence was PCR-amplified (In1-Hind-Up: 59-TCTCAAGCTTATGCCCTCCC-
CAGGGAC-39 and In1-Bam-Low: 59-TGTGGGATCCCTAGAGCTCGGG-
GCTGCAG-39) and cloned into pCDNA3.11. Empty pCDNA3.11 (mock) was used
in all the experiments as negative control. For silencing experiments, a battery of
custom-designed siRNAs specifically targeted against the unique In1-ghrelin mRNA
sequence was chemically synthesized by Life Technologies and their efficiency,
specificity and appropriate concentration tested in human cell lines expressing In1-
ghrelin (MDA-MB-231 breast cancer cell line and LnCAP prostate cancer cell line)
(data not shown). Among them, the herein named In1-ghrelin siRNA (59-
GAGTCCTAAACAGACTGTT-39) demonstrated a more robust silencing efficiency
of In1-ghrelin, but not native ghrelin, in all the models tested (data not shown). As a
negative control, a commercial, validated negative control (scramble) was used in all
the experiments, which according to the manufacturer’s instructions, has no
significant sequence similarity to murine or human gene sequences (Silencer Select
Negative Control No. 1 siRNA, Life Technologies, Green Island, NY, USA).
For transfection assays (overexpression or silencing), 200,000–500,000 cells were
seeded on 6-well plates in serum containing medium during 24–36 h. Then, medium
was replaced with antibiotic-antimycotic free medium. For overexpression experi-
ments, 100 ng/50,000 cell of ghrelin or In1-ghrelin plasmid was diluted in 50 mL of
Opti-MEM and, 0.5 mL of Lipofectamine 2000 (Life Technologies) were separately
diluted in another 50 mL of Opti-MEM. Both solutions were incubated for 5 minutes
at room temperature and then, were mixed and incubated for 30 minutes at room
temperature. After this incubation period, the solution (total of 100 mL) was added to
the cells/per well. For silencing experiments, 7.5 mL of Lipofectamine RNAiMAX
(Life Technologies) was diluted in 100 mL of Opti-MEM and, 100 nM of In1-ghrelin
siRNA was separately diluted in another 100 mL of Opti-MEM. Both solutions were
incubated for 5minutes at room temperature and then, weremixed and incubated for
30 minat room temperature. After this incubation period, the solution (total of
200 mL)was added to the cells/per well. In both cases (overexpression or silencing
experiments), the solutions added to each well were incubated for 6–8 h at 37uC and
then, medium was replacedwith serum containing medium for 18 h. Finally, cells
were detached and seeded in 96-well plates for cell viability measurements and, some
cells were collected for validation of the transfection efficiency (measure by qPCR).
Cell lines and culturing. The mouse corticotroph pituitary derived cell line AtT-20/
D16v-F2 (ATCCH CRL-1795) was cultured and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) complemented with 10% FBS, 100 U/ml penicillin/
streptomycin, 0.024 M of 2-(4(2-hydroxyethyl)-1-piperazine)-ethane sulfonic acid
(HEPES), and maintained at 37uC and 5% CO2, under sterile conditions. CHO-K1
cell line(ATCCH CCL-61) expressing recombinant human GHSR1a (GenBank
accession number U60179) or GHSR1b (GenBank accession number U60181) were
cultured and maintained in Ham’s F12 media (Corning #10-080-CV) supplemented
with 10% FBS, 2 mM L-Glutamine and 0.4 mg/mL Geneticin.
RNA isolation, reverse-transcription, qPCR of human transcripts from normal
pituitaries and tumor samples. RNA extraction, quantification, reverse-
transcription as well as the development, validation and application of qPCR to
measure the expression levels of different human transcripts have been previously
reported elsewhere by our group23,44,45. Due to asynchronically collection of samples,
total RNA was extracted from tumoral pieces with two commercial kits following the
manufacturer’s protocol: Absolutely RNA RT-PCR Miniprep Kit (Agilent, La Jolla,
CA, USA) with deoxyribonuclease treatment and AllPrep DNA/RNA/Protein Mini
Kit followed by deoxyribonuclease treatment using RNase-Free DNase Set (Qiagen,
Limburg, Netherlands). AtT-20 cell cultures were processed to isolate total RNA
using TRIzol Reagent (Life Technologies, Barcelona, Spain) following the
manufacturer’s protocol and subsequently treated with DNase (Promega, Barcelona,
Spain). In all cases, total RNA concentration and purity was assessed using Nanodrop
2000 spectrophotometer (Thermo Scientific, Wilmington, NC, USA), and
subsequently retro-transcribed using random hexamer primers and the cDNA First
Strand Synthesis kit (MRI Fermentas, Hanover, MD, USA). cDNA derived from
pituitary tissue andAtT-20 cell line were amplified by qPCR,where samples were run,
in the same plate, against a standard curve to estimate mRNA copy number (1, 101,
102, 103, 104, 105, and 106 copies of synthetic cDNA template for each transcript) and a
No-RT sample as a negative control. qPCR was performed using Brilliant II or III
SYBR Green Master Mix in the Stratagene Mx3000p instrument (Agilent, La Jolla,
CA, USA) as previously described23,44,45. Thermal profile consisted of a initial step at
95uC for 10 minutes, followed by 40 cycles of denaturation (95uC for 30 seconds),
annealing (61uC for 1 minute), and extension (72uC for 30 seconds); and finally, a
dissociation cycle to verify that only one product was amplified. In human pituitary
samples, expression levels of native ghrelin, In1-ghrelin variant, GHSR1a, GHSR1b,
MBOAT4 and ACTB were determined, when possible, while in mouse AtT-20 cell
line expression levels of native ghrelin, In2-ghrelin variant, Ghsr, Mboat4 and Actb,
Ppia and Hprt were determined. Specific sets of primers used in this study are shown
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in Supplemental Table 1. To control for variations in the amount of RNAused and the
efficiency of the reverse-transcription reaction and, the expression level (copy-
number) of each transcript was adjusted by ACTB expression in human samples, and
by a normalization factor calculated with the expression levels of Actb, Ppia and Hprt
using GeNorm 3.346 in mouse AtT-20 cell line. It should be noted that, as previously
reported44,45 and based on the stringent criteria tomaximize specificity and efficiency,
the qPCR technique, as applied, can be used to accurately quantify copy numbers for
all human transcripts included in this study.
Primary pituitary cell culture. Pituitary adenoma specimens were dispersed into
single cells by enzymatic and mechanical disruption and cultured onto tissue culture
plates in serum containing medium, as previously described23,30,47,48. Briefly, pituitary
samples were resected by endoscopic transsphenoidal surgery and transferred to
sterile cold (4uC) culture medium (S-MEM, Gibco, Madrid, Spain) supplemented
with 0.1% BSA, 0.01% L-glutamine, 1% antibiotic-antimycotic solution, and 2.5%
HEPES. Samples were minced under sterile conditions into 1–2 mm3 pieces. Some
pieces were stored at 280uC for posterior RNA isolation and, when possible, the
remaining tissue samples were washed and incubated in 30 mL S-MEM medium
supplemented 0.3% trypsin (Beckson, Dickinson andCompany, Sparks,MD,USA) in
a spinner flask (Bellco Glass, Vineland, NJ, USA) for 2 h of gentle shaking at 37uC and
then, incubation was continued for another 5 min in presence of 1 mg of DNAse I
(Roche, Mannheim, Germany). Dispersed cells were decanted by centrifugation and
then, by repeated aspiration into a smoothtipped glass Pasteur pipette. Cells
suspensions were washed once in 4.5 g/L glucose containingDMEMmedium (Gibco,
Madrid, Spain) supplemented with 0.1% BSA, 0.01% L-glutamine, 1% antibiotic-
antimycotic solution, and 2.5% HEPES. Cell number and viability was estimated by
the Trypan blue exclusion test in Neubauer chamber, where viability was always 90–
100%.
Analysis of hormone secretion. To examine the effects of ghrelin system
components (4- and/or 24 h-incubation) on pituitary hormone release from primary
pituitary adenoma and/or AtT-20 cell line, 100,000–200,000 cell/well were used. As
previously reported15, hormone concentrations were measured in the culture media
derived from human samples according to the pituitary adenoma type using
commercial ELISAs [growth hormone, GH; adrenocorticotropin, ACTH; and
prolactin, PRL (reference numbers: EIA-3552, EIA-3647 and EIA-1291, respectively;
DRG, Mountainside, NJ, USA)] following the manufacturer’s instructions. All the
information regarding specificity, detectability, and reproducibility for each of the
assays can be accessed at the web site of the company.
Measurement of free cytosolic calcium mobilization ([Ca21]i). As previously
reported, changes in [Ca21]i in single cells were measured using fura-2AM
(50,000 cells/coverslip; Molecular Probes, Eugene, OR)23,30. Briefly, primary pituitary
adenoma cells were grown onto glass cover slips for 36–48 h (35-mm plates), and
then incubated for 30 min at 37uC with fura-2AM in phenol red-free DMEM
containing 20 mM NaHCO3 (pH 7.4). Coverslips were washed with phenol red-free
DMEM and set on a Sykes-Moore chamber (Bellco Glass, Madrid, Spain) and placed
on an inverted microscope Eclipse TE2000-E (Nikon, Tokyo, Japan) coupled to a
digital camera ORCA II BT (Hamamatsu Photonics, Hamamatsu, Japan). Cells were
examined for changes in [Ca21]i after the appropriate treatment (native ghrelin, In1-
19 or In1-40) using a 403 objective with Immersion Oil Type NF (Nikon, Tokyo,
Japan) while exposed to alternating 340–380 nm light beams, and the intensity of
light emission at 505 nm was measured every 5 seconds using MetaFluor Software
(Imaging Corp., West Chester, PA, USA). Phenol red-free DMEM and ionomycin
(Sigma-Aldrich, Madrid, Spain) were used as negative and positive control,
respectively. Changes in [Ca21]i in CHO-K1 cell line expressing recombinant
GHSR1a or GHSR1b receptor were measured using Calcium 4 Explorer Kit
(Molecular Devices, Sunnyvale, CA, USA). Briefly, cells were incubated at 37uC, 5%
CO2 overnight in growth media. After 24 hours, growth media was replaced with
Calcium 4 indicating dye in HBSS buffer containing 20 mM HEPES and 0.1% BSA
and incubated for 1 hour at 37uC. Fluorescent signals were then monitored using the
FLIPR Tetra (Molecular Devices, Sunnyvale, CA, USA) during which cells were
stimulated with compounds. Dose-response curves were analyzed using GraphPad
Prism v5.04 (La Jolla, CA, USA).
Measurement of ERK1/2 and Akt signaling pathways by western blotting. 500,000
cells were cultured in 6-well plates and incubated for 8 minutes with acylated ghrelin,
acylated In-19 and vehicle-treated controls. Briefly, after the corresponding
treatment, medium was removed and cells were washed twice using PBS, detached
using a scrapper and immediately lysed in pre-warmed SDS-DTT sample buffer at
65uC (62,5 mM Tris-HCl, 2% SDS, 20% glycerol, 100 mM DTT and 0,005%
bromophenol blue) followed by sonication for 10 seconds and boiling for 5minutes at
95u C as previously described49,50. Proteins were separated by SDS-PAGE and
transferred to nitrocellulose membranes (Millipore, Darmstadt, Germany), and then
membranes were blocked with 5% non fat dry milk in Tris-buffered saline/0.05%
Tween 20 and incubated with the primary antibodies for ERK1/2, p-ERK1/2, p-Akt,
Akt and the appropriate secondary antibodies [primary total ERKs (Santa Cruz, CA,
USA); primary p-ERK1/2, p-Akt, and Akt as well as, secondary anti-rabbit antibody
from Cell Signaling (Danvers, MA, USA)]. Proteins were developed using an
enhanced chemiluminescence detection system (GE Healthcare, UK) with dyed
molecular weight markers. A densitometric analysis of the bands was carried out with
ImageJ software51. Relative phosphorylation of ERK and Akt was obtained from
normalization of p-ERK1/2 or p-Akt against the total ERK1/2 or b-Akt, respectively.
Measurements of cell viability. As previously reported, cell viability was estimated
using alamar-blue reagent (10,000 cells/well-plate; Biosource International,
Camarillo, CA, USA)30,50,52. Briefly, cells were serum-starved for 12–16 h before the
measurements and treated with serum-free medium containing 10% alamar-blue for
3 h. Reduction of alamar-blue reagent was quantified exciting at 560 nm and reading
at 590 nmusing the FlexStation III system (Molecular Devices, Sunnyvale, CA,USA).
Subsequently, media was replaced by serum-containing alamar-blue free medium
and incubated for additional 24–72 h, measuring the alamar-blue reduction every
24 h. In experiments using the AtT-20 cell line, IGF1 and Paclitaxel (Sigma-Aldrich,
Madrid, Spain) were used as positive and negative controls, respectively.
Measurements of apoptosis. To evaluate the apoptotic rate in GH-oma and ACTH-
oma cells, 150,000 cells/well were plated and cultured for 36–48 h. Then, cell cultures
were incubated for 12 h with AG, acylated In1-19, hydrogen peroxide (used as
positive control) and vehicle-treated controls. After the incubation period, culture
cells were processed as follows: step-1) media were collected, centrifuged 5 min at
1,200 rpm and, the supernatant was discarded and the pellet was maintained; step-2)
cells were washedwith PBS, detached using a cell scrapper and collected together with
the previous pellet (step-1). Then, the mixture was centrifuged 5 min at 1,200 rpm
and the supernatant was discarded while the pellet was processed following
manufacturer’s instructions of Annexin-V-FITC/propidium iodide staining assay
(Bender Medsystems, Barcelona, Spain) and measurement were carried out by flow
cytometry (Beckman Coulter, Coulter Epics XL, Madrid, Spain).
Statistical analysis. Data were evaluated for heterogeneity of variance using the
Kolmogorov–Smirnov test. Statistical differences were assessed byMann–Whitney U
test or by one-way or two-way ANOVA followed by Fisher’s test. Correlations were
studied using Spearman’s correlation test. Data are expressed as median 6
interquartile ranges or as mean 6 S.E.M. p , 0.05 was considered significant. All
statistical analyses were performed using theGraphPad Prism5 (La Jolla, CA,USA) or
the SPSS software (IBM, New York, NY, USA).
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